Introduction
There was a time when we believed that touching the heart would lead to ventricular fibrillation; that cardiac surgery was impossible; and that introducing a catheter into the human heart would be fatal. This year marks the 40th anniversary of angioplasty, and much has changed. The evolution of interventional cardiology represents the benchmark in translational science. From the first successful human coronary angioplasty on 16 September 1977 to the development of completely bioresorbable vascular scaffolds represents an incredible journey involving many disciplines, institutions, and luminaries.
Coronary arteriography
The first reported vessel catheterization was performed in 1929 by Werner Forssmann (1904-79) , a German physician who believed that the intravascular route of delivery for drugs would be safer for injection of life-saving drugs than intra-cardiac puncture. Ignoring the ban by his chief of service, using a urethral catheter inserted via incision into the antecubital vein, he confirmed the ability to access the heart by X-ray showing the tip of the catheter in his own right atrium. 1 The next major breakthrough came in 1953, when the Swedish radiologist Sven Ivar Seldinger (1921-98) , performed the first percutaneous introduction of a catheter into an artery without cutdown. 2 The first arteriography, also accidentally performed, by Frank Mason Sones (1918-85) occurred on 30 October 1958. Following ventriculography for assessment of rheumatic valvular disease, the catheter inadvertently engaged the right coronary artery. When aortography led to injection of 30 ml of contrast into a dominant right coronary artery (RCA), it was demonstrated for the first time that selective opacification of the coronary arteries was possible. 3 In 1963, Charles Dotter, Chief of Radiology at Oregon State University, inadvertently recanalized an occluded right iliac artery during abdominal aortography for renal artery stenosis and realized that it reperfused a chronically ischemic leg. In partnership with a young entrepreneur, Bill Cook, the sole employee of the now industry giant 'Cook Incorporated', came the development of the 'Dotter Dilatation Kit', two 8F and 12F Teflon catheters. These catheters were successfully used to treat an 82-year-old woman with left leg-ulcer and gangrenous toes on 16 January 1964, representing the first successful percutaneous revascularization. A. lab at CUMC is to investigate the adverse biological response to cardiovascular injury at a molecular and cellular level. Using systems biology methodologies to investigate signalling events in the propagation of pathogenic conditions they are able to integrate functional genomics and proteomics to identify novel disease mediators. These novel candidates are then interrogated in vivo using unique models of cardiovascular injury developed by them including mouse models of balloon angioplasty and stenting, venous bypass grafting and rat models of cardiopulmonary bypass and extra-corporeal membrane oxygenation. 
Melvin Paul Judkins (1923-85), a trainee of Charles Dotter in the Oregon
Radiology Department, felt the brachial access technique, which required a surgical cut-down and general anaesthesia, was suboptimal. As a result, he developed pre-shaped Teflon coated catheters, advanced over a wire with a J-shaped tip, to perform selective coronary arteriography through the femoral approach-a technique still used in thousands of catheterization laboratories all over the world today. 5 
Balloon angioplasty
Although the pioneering work of Dotter was met with great skepticism in the United States limiting its adoption, Eberhard Zeitler, the Director of Radiology at Engelskirchen recognized the genius of Dotter's work and implemented catheter based dilatation as a method of treating peripheral vascular disease in Germany. 6 
Stenting
As with so many inventions, long delays may follow their origin until application. In 1969, Charles Dotter implanted uncoated coil springs into the popliteal artery of dogs showing modest success. 9 In April 1985, Cesare 
Drug-eluting stents
Although bare metal stents drastically reduced ISR, they were unable to eliminate it. Of the four phases of vascular response to balloon dilatation; elastic recoil was eliminated by the bare metal stent, the thrombogenic phase managed by dual antiplatelet therapy, but the proliferative phase of neointimal hyperplasia and constrictive remodeling that ensued remained problematic. In 1996, Robert Falotico at Cordis, identified Sirolimus, through a systematic drug-screening process including more than 800 different drugs as a potential candidates. Sirolimus, or Rapamycin, evolved to an anti-restenotic treatment as a failed antibiotic with no apparent therapeutic utility after a series of laboratory studies identified it was a potent inhibitor of both SMC proliferation and migration. 12 The Cypher stent, coated with Sirolimus contained within a blend of PEVA and PBMA polymer, emerged from this effort as the first drug eluting stent. Near simultaneously, Boston Scientific created a drug eluting stent using Paclitaxel, an antimitotic used for the treatment of some cancers, and the Translute polymer. Eduardo Sousa, the first to implant a Palmaz-Schatz stent, also became the first to implant the Cypher stent, 13 and soon after the RAVEL study published by Marie-Claude Morice changed the field with a finding of 0% restenosis in Cypher stents compared with 28.8% in the bare metal stent (BMS) group. 14 The Taxus stent proved similarly efficacious, as the TAXUS-II study found a 2.3% 6-month restenosis rate compared with 17.9% in BMS. 15 Since these seminal studies, drug-eluting stents (DES) have evolved dramatically, incorporating thinner struts, thin durable polymers, biodegradable polymers and polymer free drug delivery systems achieving tremendous efficacy in preventing major adverse cardiovascular events. 16 
Bioresorbable scaffolds
In 1986, Gerrard Deslanti, an employee of acute coronary syndromes (ACS) approached Phillipe Gaspard with a prototype of a temporary stent, the vision of a French interventional cardiologist Christian Boyer.
At that time, considering the high risk of sub-acute stent thrombosis, the concept of placing a temporary support scaffold that could be later specific bifurcation stents, 21 and drug-eluting balloons in restenosis 22 have shown promise, questions regarding which specific patients will benefit in a cost-effective manner remain unanswered. The future of medicine, and therefore interventional cardiology, requires personalization and precision of therapy. The biological response to a fixed device or drug dose may be dramatically different dependent on age, ethnicity, and co-morbidity. As opposed to RCTs, the development, collection, analysis and interpretation of 'big data' from real world practice will afford us the opportunity to investigate combinations of patient co-morbidities, coronary anatomy and device attributes by precision medicine. Moreover, targeted individualized treatment based on patients' genetic profile provides the potential to identify poor response to drug therapy such as dual antiplatelet therapy, adverse response to device characteristics such as DES polymer or drug, or enhanced vascular healing after iatrogenic injury. 23 
Conclusion
Basic research is scientific exploration aimed to improve scientific theories for improved understanding or prediction of natural or other phenomena. Although understanding molecular and cellular mechanisms is central to the goals of science, so is the generation of new ideas, principles, and theories. Interventional cardiology, despite its youth, has a rich history of science, and may be the ideal example of the progression of science from basic through translational to clinical. At the 40th anniversary of angioplasty may we be reminded that there is no advancement without science and no future without history.
